FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileNurExone Biologic Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NRX.V
NurExone Biologic Inc. Stock AnalysisComprehensive stock analysis for NurExone Biologic Inc. (NRX.V) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNRX.V
NRX.V
NurExone Biologic Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NRX.V
  1. Home
  2. Stocks
  3. NurExone Biologic Inc.

NurExone Biologic Inc.

FRC Coverage
🇨🇦NRX.V•TSXV

NurExone Biologic Inc.

FRC Coverage
🇨🇦NRX.V•TSXV

Your view on NRX.V

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

Members onlyFRC analyst coverageFRC analyst · Dec 16, 2024
Rating
Members only
Fair valueFRC fair value
CAD$••.••
Price today
—
Upside
••%
PriceFRC fair value

About NurExone Biologic Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Dr. Lior Shaltiel
Headquarters
1 First Canadian Place Suite 1600 100 King Street West, Toronto, ON, CA

NurExone Biologic Inc., operates as a pharmaceutical technology company.

It is developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.

FRC is paid by the company for coverage·

FRC Research

Research Reports

FRC analyst coverage and recommendations.

Research Reports

FRC Research
1 report
Dec 16, 2024

A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment

NRX, an Israeli biotech company founded in 2020, is developing a novel drug delivery platform designed to provide minimally invasive

Thumbnail for A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment

FRC is paid by the company for coverage·

Analyst Notes

Ongoing commentary and updates from FRC analysts.

FRC Analyst
6 notes

Jul 21, 2025 · 1y ago · Latest

Company announcement

Preclinical study indicates significant improvement in walking quality in spinal cord injury model

Read the announcement
FRC Analyst's Comment
Positive - NRX announced that animals treated with a higher dose of ExoPTEN showed significant recovery of motor function following spinal cord injury. Results demonstrated a clear dose-dependent improvement in mobility, and walking parameters, with no side effects observed at the higher dose. These promising preclinical findings support ExoPTEN’s potential as a treatment for acute spinal cord injury. NRX will continue optimizing dosing regimen, and manufacturing processes, while preparing for further studies, and regulatory engagement, with the goal of initiating first-in-human clinical trials.

Apr 28, 2025 · 1y ago

Company announcement

Expands pipeline with promising preclinical results for facial nerve regeneratio

Read the announcement
FRC Analyst's Comment
Positive - NurExone’s lead candidate, ExoPTEN, has demonstrated significant functional recovery and nerve regeneration in a preclinical model of facial nerve injury. These findings introduce a new potential therapeutic avenue for conditions such as Bell's palsy, Ramsay Hunt Syndrome, and other facial nerve disorders. This development marks NurExone’s third therapeutic focus, complementing its existing programs in spinal cord injury, and optic nerve regeneration. We believe NRX remains on track to initiate phase one clinical trials within the next 12 months.

Apr 14, 2025 · 1y ago

Company announcement

Announces U.S. uplisting intention, and closes $2.3M private placement

Read the announcement
FRC Analyst's Comment
Positive - We believe NRX is on track to enter phase one clinical trials within 12 months. Last month, the company completed a preclinical study to support its application for an Investigational New Drug (IND) designation, a necessary step before initiating human clinical trials, for its ExoPTEN treatment for acute spinal cord injury (SCI). ExoPTEN has received orphan drug designation from the U.S. FDA, and the European Medicines Agency (EMA). We note that there is currently no cure for SCI.

FRC is paid by the company for coverage·

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Analyst Fair Value

FRC's analysts' fair value estimate and rating, from their research on the company.

About this section

FRC's fair value estimate for NurExone Biologic Inc., and the rating behind it. Set by FRC's analysts in their research on the company: the current estimate, the rating, and when it was last revised. Included with a free account.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for NurExone Biologic Inc.. Starting points for NurExone Biologic Inc.: EPS -C$0.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for NurExone Biologic Inc.. NurExone Biologic Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for NurExone Biologic Inc.. Trailing twelve-month EPS for NurExone Biologic Inc. stands at -C$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for NurExone Biologic Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold NRX.V12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ALPSAlps Group IncHealthcareNASDAQ$36.4M
ALTAltimmune, Inc.HealthcareNASDAQ$258.8M
ALXOALX Oncology Holdings Inc.HealthcareNASDAQ$137.0M
ALZNAlzamend Neuro, Inc.HealthcareNASDAQ$3.7M
AMBSAmarantus BioScience Holdings, Inc.HealthcareOTC$3,684
AMGXFAnGes, Inc.HealthcareOTC$139.1M
AMLXAmylyx Pharmaceuticals, Inc.HealthcareNASDAQ$3.3B
AMPEAmpio Pharmaceuticals, Inc.HealthcareOTC$307,285
ANABAnaptysBio, Inc.HealthcareNASDAQ$1.4B
ANEBAnebulo Pharmaceuticals, Inc.HealthcareOTC$95.7M
ANIXAnixa Biosciences, Inc.HealthcareNASDAQ$84.8M
ANLAdlai Nortye Ltd. American Depositary SharesHealthcareNASDAQ$453.8M
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for NurExone Biologic Inc.. Coverage tracks NurExone Biologic Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of NurExone Biologic Inc.